- Home
- BUD vs GILD Comparison
BUD vs GILD Comparison
Compare BUD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUD
- GILD
- Stock Information
- Founded
- BUD 1366
- GILD 1987
- Country
- BUD Belgium
- GILD United States
- Employees
- BUD N/A
- GILD N/A
- Industry
- BUD Beverages (Production/Distribution)
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BUD Consumer Staples
- GILD Health Care
- Exchange
- BUD Nasdaq
- GILD Nasdaq
- Market Cap
- BUD 110.9B
- GILD 110.9B
- IPO Year
- BUD N/A
- GILD 1992
- Fundamental
- Price
- BUD $55.20
- GILD $88.63
- Analyst Decision
- BUD Buy
- GILD Buy
- Analyst Count
- BUD 6
- GILD 24
- Target Price
- BUD $74.00
- GILD $93.91
- AVG Volume (30 Days)
- BUD 2.1M
- GILD 7.6M
- Earning Date
- BUD 10-31-2024
- GILD 11-06-2024
- Dividend Yield
- BUD 1.59%
- GILD 3.48%
- EPS Growth
- BUD 4.16
- GILD N/A
- EPS
- BUD 3.19
- GILD 0.10
- Revenue
- BUD $59,400,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- BUD $3.10
- GILD $5.71
- Revenue Next Year
- BUD $3.60
- GILD $0.37
- P/E Ratio
- BUD $16.96
- GILD $912.94
- Revenue Growth
- BUD N/A
- GILD 3.31
- 52 Week Low
- BUD $54.79
- GILD $62.07
- 52 Week High
- BUD $67.49
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- BUD 23.05
- GILD 47.16
- Support Level
- BUD $56.09
- GILD $86.08
- Resistance Level
- BUD $56.59
- GILD $98.90
- Average True Range (ATR)
- BUD 0.59
- GILD 2.21
- MACD
- BUD -0.17
- GILD -0.86
- Stochastic Oscillator
- BUD 7.64
- GILD 19.89
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 it acquired SABMiller.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.